Atavistik Bio extended its Series B with an additional $40M, bringing the round to $160M to advance its allosteric programs for blood disorders, including a lead candidate targeting hereditary hemorrhagic telangiectasia (HHT). The financing underscores investor appetite for precision medicines in rare hematologic diseases with limited treatment options. The company plans to use proceeds to support clinical trial initiation and expand the development team. The funding environment for targeted hematology programs remains active, with investors backing differentiated modalities that address genetically defined pathologies and unmet rare disease needs.